BALAXI PHARMACEUTICALS LIMITED Stock Price Today (NSE: BALAXI)
Fundamental Score
BALAXI PHARMACEUTICALS LIMITED Share Price — Live NSE/BSE Price, Fundamentals & Analysis
BALAXI PHARMACEUTICALS LIMITED share price today is ₹23.33, up +0.91% on NSE/BSE as of 16 September 2026. BALAXI PHARMACEUTICALS LIMITED (BALAXI) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹128.80 (Cr). The 52-week high for BALAXI share price is ₹47.71 and the 52-week low is ₹15.20. At a P/E ratio of 51.84x, BALAXI is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 0.59% and a debt-to-equity ratio of 0.22.
BALAXI PHARMACEUTICALS LIMITED Share Price Chart — NSE/BSE Historical Performance
BALAXI PHARMACEUTICALS LIMITED share price chart: -2.15% return over the past month. 52-week high ₹47.71, 52-week low ₹15.20.
BALAXI PHARMACEUTICALS LIMITED — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹23.01 | ₹24.33 | ₹22.50 | ₹23.33 | 19.59K (Cr) | |
| ₹24.80 | ₹24.80 | ₹23.00 | ₹23.12 | 26.07K (Cr) | |
| ₹23.40 | ₹24.69 | ₹22.75 | ₹23.39 | 39.70K (Cr) | |
| ₹24.20 | ₹24.36 | ₹22.73 | ₹23.24 | 39.29K (Cr) | |
| ₹24.18 | ₹25.05 | ₹22.70 | ₹23.68 | 87.55K (Cr) | |
| ₹24.24 | ₹24.75 | ₹23.20 | ₹23.34 | 67.89K (Cr) | |
| ₹26.00 | ₹26.00 | ₹23.50 | ₹24.24 | 69.37K (Cr) | |
| ₹26.60 | ₹26.60 | ₹24.93 | ₹25.37 | 50.78K (Cr) | |
| ₹26.99 | ₹26.99 | ₹24.41 | ₹25.80 | 2.23L (Cr) | |
| ₹22.45 | ₹25.04 | ₹22.45 | ₹25.01 | 3.03L (Cr) |
BALAXI PHARMACEUTICALS LIMITED — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹22.35 | ₹26.99 | ₹22.35 | ₹23.33 | +4.38% | |
| ₹23.67 | ₹25.40 | ₹21.50 | ₹22.34 | -5.62% | |
| ₹23.87 | ₹25.50 | ₹23.00 | ₹23.90 | +0.13% | |
| ₹27.50 | ₹27.50 | ₹22.50 | ₹23.91 | -13.05% | |
| ₹27.10 | ₹29.90 | ₹23.40 | ₹26.21 | -3.28% | |
| ₹16.03 | ₹28.63 | ₹16.03 | ₹26.63 | +66.13% | |
| ₹20.00 | ₹20.90 | ₹15.20 | ₹15.67 | -21.65% | |
| ₹25.13 | ₹25.88 | ₹19.60 | ₹19.73 | -21.49% | |
| ₹27.63 | ₹29.90 | ₹23.01 | ₹24.38 | -11.76% | |
| ₹36.95 | ₹37.22 | ₹25.86 | ₹26.87 | -27.28% | |
| ₹42.94 | ₹43.85 | ₹35.67 | ₹36.75 | -14.42% | |
| ₹43.99 | ₹45.34 | ₹40.76 | ₹42.94 | -2.39% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
BALAXI PHARMACEUTICALS LIMITED Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
BALAXI PHARMACEUTICALS LIMITED Fundamental Analysis & Valuation Benchmarking
Educational evaluation of BALAXI across key market metrics for learning purposes.
Positive Indicators
4 factors identified
Conservative Debt Levels (D/E: 0.22)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Healthy Liquidity Position (Current Ratio: 4.45)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Balanced Promoter Holding (65.99%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
11 factors identified
Below-Average Return on Equity (0.59%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (3.47%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 51.84x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-92.94%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Limited Growth History (3.15% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-63.13% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-47.99% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Weak Interest Coverage (2.36x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-74.93 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 2.56%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
BALAXI PHARMACEUTICALS LIMITED vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare BALAXI PHARMACEUTICALS LIMITED with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
15.1/100 | ₹23.33₹23 | ₹128.80₹128.80 | 51.84Average 51.8 Average | 0.59%Poor 0.59% Poor | 3.47%Poor 3.47% Poor | 0.22Excellent 0.2 Excellent | -47.99%Poor -47.99% Poor | 3.15%Average 3.15% Average | 0.00% | |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1845.80₹1846 | ₹442862.79₹442862.79 | 36.62Average 36.6 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9393.50₹9394 | ₹248927.75₹248927.75 | 85.23Average 85.2 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4943.00₹4943 | ₹167300.78₹167300.78 | 78.96Average 79.0 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1114.10₹1114 | ₹111187.18₹111187.18 | 24.83Average 24.8 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1374.50₹1375 | ₹111038.98₹111038.98 | 32.93Average 32.9 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1944.00₹1944 | ₹105024.60₹105024.60 | 95.95Average 96.0 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1666.20₹1666 | ₹95873.15₹95873.15 | 26.03Average 26.0 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1141.00₹1141 | ₹95273.50₹95273.50 | 29.49Average 29.5 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2074.00₹2074 | ₹94833.65₹94833.65 | 17.14Average 17.1 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2246.00₹2246 | ₹92759.80₹92759.80 | 45.38Average 45.4 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price442862.79 Cr
- Divi's Laboratories Limited share price248927.75 Cr
- Torrent Pharmaceuticals Limited share price167300.78 Cr
- Zydus Lifesciences Limited share price111187.18 Cr
- Cipla Limited share price111038.98 Cr
BALAXI PHARMACEUTICALS LIMITED PE Ratio History
Historical price-to-earnings ratio for BALAXI — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2023 | ₹9.08 | ₹86.47 | 9.5x |
| FY 2022 | ₹9.53 | ₹121.44 | 12.7x |
| FY 2021 | ₹7.63 | ₹102.62 | 13.5x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
BALAXI PHARMACEUTICALS LIMITED Dividend History
Annual cash dividends paid by BALAXI — dividend yield N/A
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2023 | ₹0.50 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
BALAXI PHARMACEUTICALS LIMITED Quarterly Performance
Latest quarterly metrics for BALAXI — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
14.05%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-92.94%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
3.15%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-47.99%
Compounded annual net profit growth over 5 years
BALAXI PHARMACEUTICALS LIMITED Technical Indicators
SMA 50, SMA 200, RSI and volume signals for BALAXI — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
BALAXI PHARMACEUTICALS LIMITED Financial Statements
Annual income statement, balance sheet and cash flow for BALAXI PHARMACEUTICALS LIMITED (BALAXI) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for BALAXI PHARMACEUTICALS LIMITED
About BALAXI (BALAXI PHARMACEUTICALS LIMITED)
Balaxi Pharmaceuticals Ltd is a dynamic and expanding player in the global pharmaceutical landscape, focusing on bridging critical healthcare gaps in emerging markets. With a stead...fast commitment to quality and accessibility, Balaxi operates as an international distributor, meticulously sourcing and delivering essential pharmaceutical products to regions often underserved by mainstream pharmaceutical companies. Beyond traditional distribution, Balaxi cultivates strong, localized partnerships, building robust supply chains and tailoring product offerings to meet the specific needs and regulatory landscapes of each market. Their comprehensive approach ensures that vital medications reach patients who need them most, improving health outcomes and fostering long-term relationships with healthcare providers and communities. The company's core strength lies in its diverse therapeutic portfolio, encompassing a wide range of treatments addressing prevalent health challenges in its target regions. From life-saving antibiotics combating infectious diseases to effective analgesics alleviating pain and suffering, and vital anti-malarial medications fighting the scourge of malaria, Balaxi's product range reflects its dedication to improving public health. Beyond pharmaceuticals, Balaxi recognizes the importance of holistic well-being, extending its reach into fast-moving consumer goods (FMCG) to provide essential daily necessities. This diversified approach allows Balaxi to cater to a broader range of needs within the communities it serves, further solidifying its role as a trusted and reliable partner. Balaxi Pharmaceuticals Ltd is driven by a vision of sustainable growth and social responsibility. The company's strategic focus on emerging markets, combined with its commitment to quality, innovation, and ethical business practices, positions it for continued success in the evolving global healthcare landscape. By fostering strong relationships with manufacturers, distributors, and local communities, Balaxi is building a robust and resilient business model that delivers value to all stakeholders. With a clear mission to improve access to essential medicines and consumer goods, Balaxi Pharmaceuticals Ltd is making a tangible difference in the lives of people across Africa, the Caribbean Islands, and Latin America.
Company Details
BALAXI Share Price: Frequently Asked Questions
What is the current share price of BALAXI PHARMACEUTICALS LIMITED?
BALAXI PHARMACEUTICALS LIMITED (BALAXI) trades at ₹23.33 on NSE. Market cap ₹128.80 (Cr). Educational data only.
What is the P/E ratio of BALAXI PHARMACEUTICALS LIMITED?
BALAXI PHARMACEUTICALS LIMITED has a P/E of 51.84x vs industry average 34.89x.
What is the Bull Run score for BALAXI PHARMACEUTICALS LIMITED?
BALAXI PHARMACEUTICALS LIMITED has a Bull Run score of 15.1/100 based on 25+ financial parameters.
Does BALAXI PHARMACEUTICALS LIMITED pay dividends?
BALAXI PHARMACEUTICALS LIMITED has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of BALAXI PHARMACEUTICALS LIMITED?
BALAXI PHARMACEUTICALS LIMITED has ROE of 0.59%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of BALAXI PHARMACEUTICALS LIMITED?
BALAXI PHARMACEUTICALS LIMITED has debt-to-equity of 0.22.
Is BALAXI PHARMACEUTICALS LIMITED a good investment?
Bull Run gives BALAXI PHARMACEUTICALS LIMITED a score of 15.1/100. This is not investment advice — consult a SEBI-registered advisor.